JP6401265B2 - Ｎ−（４−クロロ−２−ヒドロキシ−３−（（３ｓ）−３−ピペリジニルスルホニル）フェニル−ｎ’−（３−フルオロ−２−メチルフェニル）尿素の臭化水素酸塩 - Google Patents

Ｎ−（４−クロロ−２−ヒドロキシ−３−（（３ｓ）−３−ピペリジニルスルホニル）フェニル−ｎ’−（３−フルオロ−２−メチルフェニル）尿素の臭化水素酸塩 Download PDF

Info

Publication number
JP6401265B2
JP6401265B2 JP2016529894A JP2016529894A JP6401265B2 JP 6401265 B2 JP6401265 B2 JP 6401265B2 JP 2016529894 A JP2016529894 A JP 2016529894A JP 2016529894 A JP2016529894 A JP 2016529894A JP 6401265 B2 JP6401265 B2 JP 6401265B2
Authority
JP
Japan
Prior art keywords
disease
compound
condition
pharmaceutical composition
indicated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016529894A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537344A (ja
JP2016537344A5 (enExample
Inventor
ドミニク サンダーソン，フランシス
ドミニク サンダーソン，フランシス
マリー バランス，サラ
マリー バランス，サラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property No 2 Ltd
Original Assignee
GlaxoSmithKline Intellectual Property No 2 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property No 2 Ltd filed Critical GlaxoSmithKline Intellectual Property No 2 Ltd
Publication of JP2016537344A publication Critical patent/JP2016537344A/ja
Publication of JP2016537344A5 publication Critical patent/JP2016537344A5/ja
Application granted granted Critical
Publication of JP6401265B2 publication Critical patent/JP6401265B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016529894A 2013-11-13 2014-11-11 Ｎ−（４−クロロ−２−ヒドロキシ−３−（（３ｓ）−３−ピペリジニルスルホニル）フェニル−ｎ’−（３−フルオロ−２−メチルフェニル）尿素の臭化水素酸塩 Expired - Fee Related JP6401265B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1320021.7 2013-11-13
GBGB1320021.7A GB201320021D0 (en) 2013-11-13 2013-11-13 Novel Compounds
PCT/EP2014/074222 WO2015071235A1 (en) 2013-11-13 2014-11-11 Hydrobromide salt ofn-(4-chloro-2-hydroxy-3-((3s)-3-piperidinylsulfonyl)phenyl-n'-(3-fluoro-2-methylphenyl)urea

Publications (3)

Publication Number Publication Date
JP2016537344A JP2016537344A (ja) 2016-12-01
JP2016537344A5 JP2016537344A5 (enExample) 2018-02-08
JP6401265B2 true JP6401265B2 (ja) 2018-10-10

Family

ID=49818555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016529894A Expired - Fee Related JP6401265B2 (ja) 2013-11-13 2014-11-11 Ｎ−（４−クロロ−２−ヒドロキシ−３−（（３ｓ）−３−ピペリジニルスルホニル）フェニル−ｎ’−（３−フルオロ−２−メチルフェニル）尿素の臭化水素酸塩

Country Status (24)

Country Link
US (3) US9809540B2 (enExample)
EP (1) EP3068763B1 (enExample)
JP (1) JP6401265B2 (enExample)
KR (1) KR20160083950A (enExample)
CN (1) CN105683162A (enExample)
AU (1) AU2014350334B2 (enExample)
BR (1) BR112016010409A8 (enExample)
CA (1) CA2929907A1 (enExample)
CY (1) CY1121581T1 (enExample)
DK (1) DK3068763T3 (enExample)
ES (1) ES2714721T3 (enExample)
GB (1) GB201320021D0 (enExample)
HR (1) HRP20190449T1 (enExample)
HU (1) HUE041873T2 (enExample)
LT (1) LT3068763T (enExample)
ME (1) ME03328B (enExample)
PL (1) PL3068763T3 (enExample)
PT (1) PT3068763T (enExample)
RS (1) RS58382B1 (enExample)
RU (1) RU2685408C1 (enExample)
SI (1) SI3068763T1 (enExample)
SM (1) SMT201900156T1 (enExample)
TR (1) TR201902981T4 (enExample)
WO (1) WO2015071235A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107072976A (zh) * 2014-05-12 2017-08-18 葛兰素史克知识产权第二有限公司 用于治疗传染性疾病的包含Danirixin的药物组合物
BR112018011138A2 (pt) * 2015-11-30 2018-11-21 Glaxosmithkline Intellectual Property (No. formulações para administração intravenosa
WO2018073248A1 (en) 2016-10-17 2018-04-26 Icm (Institut Du Cerveau Et De La Moelle Épinière) Prognosis of demyelinating diseases patients and treatment thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2009992B1 (en) * 2006-04-21 2012-06-27 GlaxoSmithKline LLC Il-8 receptor antagonists

Also Published As

Publication number Publication date
CY1121581T1 (el) 2020-05-29
HUE041873T2 (hu) 2019-05-28
US10604485B2 (en) 2020-03-31
LT3068763T (lt) 2019-03-12
EP3068763A1 (en) 2016-09-21
AU2014350334B2 (en) 2017-08-10
JP2016537344A (ja) 2016-12-01
US20190112269A1 (en) 2019-04-18
PL3068763T3 (pl) 2019-05-31
RU2685408C1 (ru) 2019-04-18
ES2714721T3 (es) 2019-05-29
TR201902981T4 (tr) 2019-03-21
US20160264525A1 (en) 2016-09-15
PT3068763T (pt) 2019-03-20
CA2929907A1 (en) 2015-05-21
ME03328B (me) 2019-10-20
RS58382B1 (sr) 2019-04-30
CN105683162A (zh) 2016-06-15
AU2014350334A1 (en) 2016-06-02
EP3068763B1 (en) 2018-12-19
SMT201900156T1 (it) 2019-05-10
WO2015071235A1 (en) 2015-05-21
BR112016010409A8 (pt) 2020-04-22
SI3068763T1 (sl) 2019-04-30
RU2016116955A (ru) 2017-12-19
US20180079722A1 (en) 2018-03-22
HRP20190449T1 (hr) 2019-04-19
DK3068763T3 (en) 2019-03-18
KR20160083950A (ko) 2016-07-12
GB201320021D0 (en) 2013-12-25
US9809540B2 (en) 2017-11-07

Similar Documents

Publication Publication Date Title
ES2236833T3 (es) Compuestos heterociclicos de guanidinilo utiles como agonistas de receptores adrenergicos alfa 2.
JP2011516442A (ja) 筋ジストロフィーを治療するための化合物
CA3075305A1 (en) Cxcr-2 inhibitors for treating disorders
JP6381523B2 (ja) Ｐｉ−３キナーゼ阻害剤の投与レジメン
US10604485B2 (en) Hydrobromide salt of N-(4-chloro-2-hydroxy-3-((3S)-3-piperidinylsulfonyl)phenyl-N′-(3-Fluoro-2-methylphenyl)urea
JP7667764B2 (ja) 線維症疾患の治療及び／又は予防用アミノナフトキノン化合物
CA3017345A1 (en) Cxcr-2 inhibitors for treating crystal arthropathy disorders
JP5726301B2 (ja) 新規抗ヒスタミン剤
WO2019224774A1 (en) Heterocyclic amides as rip1 kinase inhibitors
CN111620815B (zh) 手性氯喹、羟氯喹和其衍生物及其制备方法与用途
JP2009507921A (ja) ピペラジン化合物のグルクロン酸塩
JPH09511483A (ja) α−２−アドレノセプター作動剤として有用な６−（２−イミダゾリニルアミノ）キノリン化合物
CN104628708A (zh) 一种阿伐那非的晶型及其制备方法、用途和药物组合物
HUE028761T2 (en) Crystalline form of a succinate salt
CN114539130B (zh) 苯基哌嗪或苯基哌啶类化合物及其应用
JPWO1994020107A1 (ja) 移植組織の拒絶反応抑制剤
JP2007518768A (ja) 有機化合物の組み合わせ物
JP2022532186A (ja) 非晶質のｐｉ３ｋ阻害剤及びこれを含有する医薬組成物
JP2009507923A (ja) 持続放出製剤およびこれの使用
CN1981764A (zh) α－(吗啉－1－基)甲基－2－甲基－5－硝基咪唑－1－乙醇在制备抗滴虫、抗阿米巴原虫药物的用途
RU2161967C2 (ru) Соединения 7-(2-имидазолиниламино) хинолина, пригодные в качестве агонистов альфа-2-адренорецептора
TW200914009A (en) Use of 4-cyclopropylmethoxy-N-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the preparation of a medicament for use in the treatment of cranial traumas
JP2008543770A (ja) （５ｚ）−５−（６−キノキサリニルメチリデン）−２−［（２，６−ジクロロフェニル）アミノ］−１，３−チアゾール−４（５ｈ）−オン
JPWO2006082820A1 (ja) 性器ヘルペス治療剤
JP2010510995A (ja) ５−［（２ｒ）−［２−［２−［２−（２，２，２−トリフルオロエトキシ）フェノキシ］エチル］アミノ］プロピル］−２−メトキシベンゼンスルホンアミド

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171219

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20171219

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20180423

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180424

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180821

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180906

R150 Certificate of patent or registration of utility model

Ref document number: 6401265

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees